By Martin Baccardax “We are excited to announce Pfizer’s proposed acquisition of Biohaven, recognizing the market leadership of Nurtec, our breakthrough all in one migraine therapy,” said CEO Vlad Coric. Biohaven Pharmaceutical (BHVN) – Get Biohaven Pharmaceutical Holding Company Ltd. Report shares rocketed higher Tuesday after the maker of the migraine treatment nurtec, which was once endorsed by Khloé Kardashian, agreed to an $11.6 billion all-cash takeover by Pfizer (PFE) – Get Pfizer Inc. Report. Pfizer, which built a 2.6% stake in Biohaven last November, will pay $148.5 in cash for the re…